|
1
|
Jungk C, Chatziaslanidou D, Ahmadi R,
Capper D, Bermejo JL, Exner J, von Deimling A, Herold-Mende C and
Unterberg A: Chemotherapy with BCNU in recurrent glioma: Analysis
of clinical outcome and side effects in chemotherapy-naive
patients. BMC Cancer. 16:812016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wu CX, Lin GS, Lin ZX, Zhang JD, Chen L,
Liu SY, Tang WL, Qiu XX and Zhou CF: Peritumoral edema on magnetic
resonance imaging predicts a poor clinical outcome in malignant
glioma. Oncol Lett. 10:2769–2776. 2015.PubMed/NCBI
|
|
3
|
Hatanpaa KJ, Burma S, Zhao D and Habib AA:
Epidermal growth factor receptor in glioma: Signal transduction,
neuropathology, imaging, and radioresistance. Neoplasia.
12:675–684. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cohen AL, Holmen SL and Colman H: IDH1 and
IDH2 mutations in gliomas. Curr Neurol Neurosci Rep. 13:3452013.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Endersby R and Baker SJ: PTEN signaling in
brain: Neuropathology and tumorigenesis. Oncogene. 27:5416–5430.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Komori T, Sasaki H and Yoshida K: Revised
WHO classification of tumours of the central nervous system:
Summary of the revision and perspective. No Shinkei Geka.
44:625–635. 2016.(In Japanese). PubMed/NCBI
|
|
7
|
Minniti G, Muni R, Lanzetta G, Marchetti P
and Enrici RM: Chemotherapy for glioblastoma: Current treatment and
future perspectives for cytotoxic and targeted agents. Anticancer
Res. 29:5171–5184. 2009.PubMed/NCBI
|
|
8
|
Schwartzbaum JA, Fisher JL, Aldape KD and
Wrensch M: Epidemiology and molecular pathology of glioma. Nat Clin
Pract Neurol. 2:494–503. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yan Y, Peng Y, Ou Y and Jiang Y:
MicroRNA-610 is downregulated in glioma cells, and inhibits
proliferation and motility by directly targeting MDM2. Mol Med Rep.
14:2657–2664. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wen PY and Kesari S: Malignant gliomas in
adults. N Engl J Med. 359:492–507. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Furnari FB, Fenton T, Bachoo RM, Mukasa A,
Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, et al:
Malignant astrocytic glioma: Genetics, biology, and paths to
treatment. Genes Dev. 21:2683–2710. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pollack IF: Neuro-oncology: Therapeutic
benefits of reirradiation for recurrent brain tumors. Nat Rev
Neurol. 6:533–535. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ameres SL and Zamore PD: Diversifying
microRNA sequence and function. Nat Rev Mol Cell Biol. 14:475–488.
2013. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Osaki M, Okada F and Ochiya T: miRNA
therapy targeting cancer stem cells: A new paradigm for cancer
treatment and prevention of tumor recurrence. Ther Deliv.
6:323–337. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hwang HW and Mendell JT: MicroRNAs in cell
proliferation, cell death, and tumorigenesis. Br J Cancer. 96
Suppl:R40–R44. 2007.PubMed/NCBI
|
|
17
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bushati N and Cohen SM: MicroRNA
functions. Annu Rev Cell Dev Biol. 23:175–205. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu X, Wang S, Yuan A, Yuan X and Liu B:
MicroRNA-140 represses glioma growth and metastasis by directly
targeting ADAM9. Oncol Rep. 36:2329–2338. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Guan H, Liu C, Fang F, Huang Y, Tao T,
Ling Z, You Z, Han X, Chen S, Xu B and Chen M: MicroRNA-744
promotes prostate cancer progression through aberrantly activating
Wnt/β-catenin signaling. Oncotarget. 8:14693–14707. 2017.PubMed/NCBI
|
|
21
|
Qi M, Liu D and Zhang S: MicroRNA-21
contributes to the discrimination of chemoresistance in metastatic
gastric cancer. Cancer Biomark. 18:451–458. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
An N, Luo X, Zhang M and Yu R:
MicroRNA-376b promotes breast cancer metastasis by targeting Hoxd10
directly. Exp Ther Med. 13:79–84. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang Y, An J, Lv W, Lou T, Liu Y and Kang
W: miRNA-129-5p suppresses cell proliferation and invasion in lung
cancer by targeting microspherule protein 1, E-cadherin and
vimentin. Oncol Lett. 12:5163–5169. 2016.PubMed/NCBI
|
|
24
|
Lu J, Getz G, Miska EA, Alvarez-Saavedra
E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA,
et al: MicroRNA expression profiles classify human cancers. Nature.
435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Peng Z, Wu T, Li Y, Xu Z, Zhang S, Liu B,
Chen Q and Tian D: MicroRNA-370-3p inhibits human glioma cell
proliferation and induces cell cycle arrest by directly targeting
β-catenin. Brain Res. 1644:53–61. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hao Y, Zhang S, Sun S, Zhu J and Xiao Y:
miR-595 targeting regulation of SOX7 expression promoted cell
proliferation of human glioblastoma. Biomed Pharmacother.
80:121–126. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fan C, Lin Y, Mao Y, Huang Z, Liu AY, Ma
H, Yu D, Maitikabili A, Xiao H, Zhang C, et al: MicroRNA-543
suppresses colorectal cancer growth and metastasis by targeting
KRAS, MTA1 and HMGA2. Oncotarget. 7:21825–21839. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bing L, Hong C, Li-Xin S and Wei G:
MicroRNA-543 suppresses endometrial cancer oncogenicity via
targeting FAK and TWIST1 expression. Arch Gynecol Obstet.
290:533–541. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bi M, Chen W, Yu H, Wang J, Ding F, Tang
DJ and Tang C: miR-543 is up-regulated in gefitinib-resistant
non-small cell lung cancer and promotes cell proliferation and
invasion via phosphatase and tensin homolog. Biochem Biophys Res
Commun. 480:369–374. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Fritzsche FR, Wassermann K, Jung M, Tölle
A, Kristiansen I, Lein M, Johannsen M, Dietel M, Jung K and
Kristiansen G: ADAM9 is highly expressed in renal cell cancer and
is associated with tumour progression. BMC Cancer. 8:1792008.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tao K, Qian N, Tang Y, Ti Z, Song W, Cao D
and Dou K: Increased expression of a disintegrin and
metalloprotease-9 in hepatocellular carcinoma: Implications for
tumor progression and prognosis. Jpn J Clin Oncol. 40:645–651.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li J, Ji Z, Qiao C, Qi Y and Shi W:
Overexpression of ADAM9 Promotes Colon Cancer Cells Invasion. J
Invest Surg. 26:127–133. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liu N, Zhang L, Wang Z, Cheng Y, Zhang P,
Wang X, Wen W, Yang H, Liu H, Jin W, et al: MicroRNA-101 inhibits
proliferation, migration and invasion of human glioblastoma by
targeting SOX9. Oncotarget. 8:19244–19254. 2017.PubMed/NCBI
|
|
35
|
Li D, Wang Z, Chen Z, Lin L, Wang Y,
Sailike D, Luo K, Du G, Xiang X and Jiafu GD: MicroRNA-106a-5p
facilitates human glioblastoma cell proliferation and invasion by
targeting adenomatosis polyposis coli protein. Biochem Biophys Res
Commun. 481:245–250. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang J, Liu H, Tian L, Wang F, Han L,
Zhang W and Bai YA: miR-15b Inhibits the progression of
glioblastoma cells through targeting insulin-like growth factor
receptor 1. Horm Cancer. 8:49–57. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Karsy M, Arslan E and Moy F: Current
progress on understanding MicroRNAs in glioblastoma multiforme.
Genes Cancer. 3:3–15. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yu L, Zhou L, Cheng Y, Sun L, Fan J, Liang
J, Guo M, Liu N and Zhu L: MicroRNA-543 acts as an oncogene by
targeting PAQR3 in hepatocellular carcinoma. Am J Cancer Res.
4:897–906. 2014.PubMed/NCBI
|
|
39
|
Li J, Dong G, Wang B, Gao W and Yang Q:
miR-543 promotes gastric cancer cell proliferation by targeting
SIRT1. Biochem Biophys Res Commun. 469:15–21. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhang H, Guo X, Feng X, Wang T, Hu Z, Que
X, Tian Q, Zhu T, Guo G, Huang W and Li X: miRNA-543 promotes
osteosarcoma cell proliferation and glycolysis by partially
suppressing PRMT9 and stabilizing HIF-1α protein. Oncotarget.
8:2342–2355. 2017.PubMed/NCBI
|
|
41
|
Yu Z, Ni L, Chen D, Zhang Q, Su Z, Wang Y,
Yu W, Wu X, Ye J, Yang S, et al: Identification of miR-7 as an
oncogene in renal cell carcinoma. J Mol Histol. 44:669–677. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Song L, Yang J, Duan P, Xu J, Luo X, Luo
F, Zhang Z, Hou T, Liu B and Zhou Q: MicroRNA-24 inhibits
osteosarcoma cell proliferation both in vitro and in vivo by
targeting LPAATβ. Arch Biochem Biophys. 535:128–135. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wu X, Zhong D, Gao Q, Zhai W, Ding Z and
Wu J: MicroRNA-34a inhibits human osteosarcoma proliferation by
downregulating ether à go-go 1 expression. Int J Med Sci.
10:676–682. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Blobel CP: ADAMs: Key components in EGFR
signalling and development. Nat Rev Mol Cell Biol. 6:32–43. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Nath D, Slocombe PM, Stephens PE, Warn A,
Hutchinson GR, Yamada KM, Docherty AJ and Murphy G: Interaction of
metargidin (ADAM-15) with alphavbeta3 and alpha5beta1 integrins on
different haemopoietic cells. J Cell Sci. 112:579–587.
1999.PubMed/NCBI
|
|
46
|
Edwards DR, Handsley MM and Pennington CJ:
The ADAM metalloproteinases. Mol Aspects Med. 29:258–289. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Guaiquil V, Swendeman S, Yoshida T,
Chavala S, Campochiaro PA and Blobel CP: ADAM9 is involved in
pathological retinal neovascularization. Mol Cell Biol.
29:2694–2703. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Duffy MJ, McKiernan E, O'Donovan N and
McGowan PM: Role of ADAMs in cancer formation and progression. Clin
Cancer Res. 15:1140–1144. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zhang J, Qi J, Chen N, Fu W, Zhou B and He
A: High expression of a disintegrin and metalloproteinase-9
predicts a shortened survival time in completely resected stage I
non-small cell lung cancer. Oncol Lett. 5:1461–1466.
2013.PubMed/NCBI
|
|
50
|
Fritzsche FR, Jung M, Tölle A, Wild P,
Hartmann A, Wassermann K, Rabien A, Lein M, Dietel M, Pilarsky C,
et al: ADAM9 expression is a significant and independent prognostic
marker of PSA relapse in prostate cancer. Eur Urol. 54:1097–1106.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Grutzmann R, Lüttges J, Sipos B, Ammerpohl
O, Dobrowolski F, Alldinger I, Kersting S, Ockert D, Koch R,
Kalthoff H, et al: ADAM9 expression in pancreatic cancer is
associated with tumour type and is a prognostic factor in ductal
adenocarcinoma. Br J Cancer. 90:1053–1058. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Fan X, Wang Y, Zhang C, Liu L, Yang S,
Wang Y, Liu X, Qian Z, Fang S, Qiao H and Jiang T: ADAM9 expression
is associate with glioma tumor grade and histological type and acts
as a prognostic factor in lower-grade gliomas. Int J Mol Sci.
17(pii): E12762016. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Chen CM, Hsieh YH, Hwang JM, Jan HJ, Hsieh
SC, Lin SH and Lai CY: Fisetin suppresses ADAM9 expression and
inhibits invasion of glioma cancer cells through increased
phosphorylation of ERK1/2. Tumour Biol. 36:3407–3415. 2015.
View Article : Google Scholar : PubMed/NCBI
|
